Neuronetics Company Leadership
STIM Stock | USD 4.49 0.04 0.90% |
Neuronetics employs about 716 people. The company is managed by 14 executives with a total tenure of roughly 1671 years, averaging almost 119.0 years of service per executive, having 51.14 employees per reported executive. Analysis of Neuronetics' management performance can provide insight into the firm performance.
Insider Sentiment 50
Impartial
Selling | Buying |
Latest Trades
2025-05-12 | Stephen Furlong | Disposed 193460 @ 4.27 | View | ||
2025-03-04 | William Andrew Macan | Disposed 377 @ 4.48 | View | ||
2025-02-14 | Stephen Furlong | Disposed 17307 @ 4.11 | View | ||
2025-02-12 | William Andrew Macan | Disposed 12175 @ 3.83 | View | ||
2025-02-10 | Keith J Sullivan | Disposed 40992 @ 3.28 | View | ||
2024-10-08 | William Andrew Macan | Disposed 1541 @ 0.82 | View | ||
2024-09-12 | Robert Cascella | Acquired 100000 @ 0.75 | View | ||
2024-09-05 | Glenn P Muir | Acquired 25000 @ 0.8 | View | ||
2024-08-28 | Glenn P Muir | Acquired 12776 @ 0.85 | View | ||
2024-08-19 | Robert Cascella | Acquired 4000 @ 1.14 | View | ||
2024-08-16 | Robert Cascella | Acquired 35000 @ 1.06 | View | ||
2024-08-14 | Robert Cascella | Acquired 35000 @ 0.79 | View |
Monitoring Neuronetics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Neuronetics | Build AI portfolio with Neuronetics Stock |
Neuronetics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Neuronetics' future performance. Based on our forecasts, it is anticipated that Neuronetics will maintain a workforce of about 720 employees by August 2025.Neuronetics Management Team Effectiveness
The company has return on total asset (ROA) of (0.1939) % which means that it has lost $0.1939 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.445) %, meaning that it created substantial loss on money invested by shareholders. Neuronetics' management efficiency ratios could be used to measure how well Neuronetics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of July 2025, Return On Tangible Assets is likely to drop to -0.45. In addition to that, Return On Capital Employed is likely to drop to -0.33. At this time, Neuronetics' Asset Turnover is very stable compared to the past year.As of the 27th of July 2025, Common Stock Shares Outstanding is likely to drop to about 19.4 M. In addition to that, Net Loss is likely to drop to about (35.1 M)
Neuronetics Workforce Comparison
Neuronetics is currently regarded as top stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 2,266. Neuronetics totals roughly 716 in number of employees claiming about 32% of equities under Health Care industry.
Neuronetics Profit Margins
The company has Profit Margin (PM) of (0.54) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.34) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.34.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.84 | 0.7232 |
|
|
Neuronetics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neuronetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neuronetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Neuronetics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-06-01 | 3.0 | 6 | 2 | 186,250 | 200,000 |
2025-03-01 | 0.9091 | 10 | 11 | 1,301,664 | 169,708 |
2024-12-01 | 1.5 | 3 | 2 | 735,000 | 2,909 |
2024-09-01 | 3.3333 | 10 | 3 | 309,171 | 47,924 |
2024-03-01 | 0.3571 | 5 | 14 | 520,000 | 200,569 |
2023-09-01 | 0.5 | 2 | 4 | 57,000 | 22,185 |
2023-06-01 | 3.5 | 7 | 2 | 263,639 | 300,996 |
2023-03-01 | 0.2917 | 7 | 24 | 677,019 | 468,531 |
2022-12-01 | 0.1 | 1 | 10 | 100,000 | 320,968 |
2022-03-01 | 0.6 | 6 | 10 | 709,872 | 60,755 |
2021-12-01 | 2.0 | 4 | 2 | 42,797 | 15,594 |
2021-09-01 | 0.5 | 2 | 4 | 25,616 | 60,140 |
2021-06-01 | 1.0 | 7 | 7 | 45,940 | 61,159 |
2021-03-01 | 1.25 | 10 | 8 | 495,427 | 112,293 |
2020-06-01 | 1.75 | 7 | 4 | 182,500 | 30,996 |
2020-03-01 | 5.0 | 20 | 4 | 874,523 | 22,635 |
2019-09-01 | 1.5 | 6 | 4 | 220,430 | 59,213 |
2019-06-01 | 1.5833 | 19 | 12 | 150,134 | 138,961 |
2019-03-01 | 3.5 | 14 | 4 | 298,177 | 52,476 |
2018-09-01 | 1.4762 | 31 | 21 | 6,336,316 | 6,223,355 |
Neuronetics Notable Stakeholders
A Neuronetics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Neuronetics often face trade-offs trying to please all of them. Neuronetics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Neuronetics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Keith Sullivan | CEO President | Profile | |
Stephen MS | Senior CEO | Profile | |
Andrew JD | General VP | Profile | |
MBA CMA | Chief Officer | Profile | |
Lisa MetznerRosas | Senior Officer | Profile | |
Andrew Macan | Gen VP | Profile | |
Claire Sears | VP Marketing | Profile | |
Rick Grubbs | Senior Accounts | Profile | |
Cory Anderson | Senior Clinical | Profile | |
Kara Thornton | VP Director | Profile | |
Rusty Page | Senior Quality | Profile | |
William Leonard | Chief Officer | Profile | |
Geoffrey MD | Chief Officer | Profile | |
Sara Grubbs | Senior Officer | Profile |
About Neuronetics Management Performance
The success or failure of an entity such as Neuronetics often depends on how effective the management is. Neuronetics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Neuronetics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Neuronetics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.43) | (0.45) | |
Return On Capital Employed | (0.32) | (0.33) | |
Return On Assets | (0.31) | (0.33) | |
Return On Equity | (1.58) | (1.50) |
Neuronetics Workforce Analysis
Traditionally, organizations such as Neuronetics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Neuronetics within its industry.Neuronetics Manpower Efficiency
Return on Neuronetics Manpower
Revenue Per Employee | 104.6K | |
Revenue Per Executive | 5.3M | |
Net Loss Per Employee | 61.1K | |
Net Loss Per Executive | 3.1M | |
Working Capital Per Employee | 37.5K | |
Working Capital Per Executive | 1.9M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.32) | Revenue Per Share | Quarterly Revenue Growth 0.836 | Return On Assets | Return On Equity |
The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.